In regulated manufacturing, a maintenance record is audit evidence. That changes what a CMMS has to be, and as AI moves into the workflow, the bar is about to rise again.
A general-purpose CMMS no longer meets the compliance demands on life sciences operations. In most factories, a maintenance management system is simply an operational tool. It tracks work orders, schedules preventive tasks, and keeps spare parts moving. In a pharmaceutical, biological, or medical device operation, however, a CMMS is integrated into the compliance infrastructure.
This distinction is easy to state and surprisingly difficult to engineer.
The trouble with “good enough”
In a regulated environment, the difference between a configurable platform and a purpose-built one becomes obvious. For years, audit readiness in life sciences meant paper records and binders: hours logged by hand, trips back to the shop to check a folder, and a scramble whenever an inspection loomed. The risk in that model is rarely the maintenance budget. It is the moment a compliance gap turns into an operational shutdown, and the cost moves to the P&L.
Most maintenance platforms are built for speed and flexibility: configure quickly, get teams logging work, iterate later. That instinct serves discrete manufacturing well. In a GxP environment it creates friction, because validation teams need something closer to the opposite: predictable, testable configurations that behave the same way every time and can be documented as such.
The gaps tend to surface in the details:
- Calibration that depends on more than one tolerance. A standard “as-left” check against a single value is fine until a process requires both as-found and as-left comparisons, plus a separate tolerance loop entirely.
- Asset location audits, where a periodic sweep has to reconcile serial numbers against expected locations, raise a controlled work order for anything missing, capture the new location, and update the master record on closeout.
- Closed-loop change control, rather than the simpler maintenance workflow most systems assume by default.
- Document behaviour that is genuinely GxP-ready, not asset management with files bolted on.
None of these are exotic. They are simply what regulated maintenance looks like.
What “cross-functional” really means
The market is maturing past “configure it yourself” toward configurations that already understand the regulatory context. One pattern has surprised teams configuring these systems: life sciences customers rarely want maintenance to sit in its own silo. They ask for shared visibility across engineering, quality, validation and operations inside one system, rather than stitching together separate tools for each department. The requirement is flexibility: workflows that bend to a specific real-world circumstance, without sacrificing traceability. In a regulated setting those two goals usually pull against each other. Reconciling them is the real design problem.
That thinking sits behind a recent collaboration between eMaint and ABS Consulting, which pairs a validatable CMMS platform with two decades of life sciences compliance expertise to produce a pre-configured starting point: workflows, calibration logic, location-audit processes and validation-file handling built in from day one, rather than scoped from scratch over months. The wider point is not any one product.
The next bar: governing AI in a validated environment
Life sciences organisations that build inspection-ready habits into their maintenance operations will be the ones able to adopt AI with confidence rather than caution. Here is where the conversation is heading, and quickly. As predictive and prescriptive capabilities move into maintenance, the shift the industry has labelled Industry 5.0, life sciences will demand more of them than almost any other sector. Four questions are already coming up in nearly every serious discussion:
- Context of use. Before an algorithm informs a maintenance decision, what exactly is it being used for, on which assets, within what limits? In a validated environment, Context of Use is not a nicety: it is the boundary that makes a tool qualifiable.
- Explainability over the black box. A model that says “replace this pump” without showing its reasoning is difficult to validate and harder to defend in an audit. Regulated manufacturers will favour systems that can show their working.
- Audit trails for AI-driven decisions. If a recommendation triggers, or defers, a maintenance action, that decision needs the same tracing and traceability as a human one. The audit trail has to extend to the algorithm.
- The EU AI Act. New obligations around risk, transparency and human oversight are arriving, and they will land on industrial software as they land elsewhere. Tooling that already treats traceability as a first principle will adapt far more comfortably than tooling that treats it as an afterthought.
The encouraging part is that none of this is new ground for life sciences. These are the same instincts the sector already applies to equipment and software validation: define the intended use, document the reasoning, keep an audit trail, design for inspection.
The throughline
A CMMS built for regulated reality, rather than retrofitted to it, is starting to look less like a luxury and more like the baseline. Whether the subject is a calibration tolerance or a machine-learning model, the principle holds: in life sciences, traceability is not the thing that slows you down. It is the thing that lets you move (to digitise, to standardise across sites, and now to bring AI into the workflow) without betting the audit on it.
These are the questions, and the day-one configuration work behind them, at the center of an upcoming webinar, Audit-Ready from Day One: A CMMS Built for Life Sciences, co-hosted by ABS Consulting and eMaint on July 29 at 11:00 a.m. PT. It’s a closer look at how teams are turning the principles above into validated starting points rather than multi-month builds.
For more articles like this, visit our Digital Transformation channel.
